Literature DB >> 7913275

NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line.

B A Antoni1, A B Rabson, A Kinter, M Bodkin, G Poli.   

Abstract

J delta K cells were isolated as a chronically infected survivor cell line, following infection of Jurkat CD4+ T cells with dl-NF, a mutated strain of human immunodeficiency virus type 1 (HIV-1) containing a deletion of the long terminal repeat (LTR) NF-kappa B sites. J delta K cells exhibited very low levels of constitutive HIV production. HIV-1 expression was activated from J delta K cells by treatment with phorbol myristate acetate (PMA), sodium butyrate (NaB), or hexamethylene bisacetamide (HMBA), but not tumor necrosis factor alpha (TNF-alpha), confirming the role of NF-kappa B in mediating TNF-alpha induction of HIV transcription. The strong induction of HIV expression by NaB or HMBA in J delta K cells clearly demonstrates the existence of NF-kappa B-independent mechanisms of HIV activation in chronically infected cells. J delta K cells may provide a useful model for characterizing NF-kappa B-independent transcriptional activation of the HIV LTR.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913275     DOI: 10.1006/viro.1994.1390

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  27 in total

Review 1.  Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Methods       Date:  2010-10-21       Impact factor: 3.608

2.  Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.

Authors:  Hung-Chih Yang; Lin Shen; Robert F Siliciano; Joel L Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-31       Impact factor: 11.205

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

4.  NF-kappa B homodimer binding within the HIV-1 initiator region and interactions with TFII-I.

Authors:  M A Montano; K Kripke; C D Norina; P Achacoso; L A Herzenberg; A L Roy; G P Nolan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Blood       Date:  2008-10-10       Impact factor: 22.113

6.  Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1.

Authors:  F Demarchi; F d'Adda di Fagagna; A Falaschi; M Giacca
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Authors:  Laura J Martins; Pawel Bonczkowski; Adam M Spivak; Ward De Spiegelaere; Camille L Novis; Ana Beatriz DePaula-Silva; Eva Malatinkova; Wim Trypsteen; Alberto Bosque; Linos Vanderkerckhove; Vicente Planelles
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-14       Impact factor: 2.205

8.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

9.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.

Authors:  Albert Jordan; Dwayne Bisgrove; Eric Verdin
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

10.  BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.

Authors:  Daniela Boehm; Vincenzo Calvanese; Roy D Dar; Sifei Xing; Sebastian Schroeder; Laura Martins; Katherine Aull; Pao-Chen Li; Vicente Planelles; James E Bradner; Ming-Ming Zhou; Robert F Siliciano; Leor Weinberger; Eric Verdin; Melanie Ott
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.